Arvinas Inc (ARVN) is a Healthcare · Biotechnology company listed on NASDAQ. Price $8.29 (-0.24%), Market cap $0.61B, 52-week low–high $6.24 ~ $13.83.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D m
Financial statements, price targets, institutional (13F) holdings and related news for Arvinas Inc are updated in real time on BlackAll Trade.
Arvinas Inc trades at $8.29 (-0.24%). Real-time quotes and charts are available on BlackAll Trade.
Arvinas Inc has a market cap of about $0.61B.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis t